The association between obesity and type 2 diabetes mellitus (T2DM) is well established, with obesity being a major modifiable risk factor in T2DM development.
I NTRO D U C TIO N
The association between obesity and type 2 diabetes mellitus (T2DM) is well established, with obesity being a major modifiable risk factor in T2DM development. (1) The main goal of achieving good glycaemic control is to reduce the risk of DM-related micro-and macrovascular complications, which contribute to the major morbidity and mortality in patients with T2DM. (2, 3) Despite an increasing armamentarium of advanced therapies for the treatment of T2DM, the number of patients achieving good glycaemic control remains dismally low. (4) In 1995, Pories et al observed that gastric bypass (GB) surgery for morbid obesity could achieve and sustain euglycaemia in 83% of patients with T2DM and 99% of patients with glucose impairment, even 14 years after surgery. (5) Since then, there has been a growing body of evidence that bariatric surgery, originally intended to effect sustainable and drastic weight loss in the morbidly obese, has substantial beneficial effects on obesity-related metabolic conditions, improving glycaemic control in T2DM (6) and reducing rates of cardiovascular disease (7) and death. (8) As a result, bariatric surgery is now known as metabolic-bariatric surgery (MBS) (9) and increasingly considered in the management of obesity-related metabolic disease, particularly T2DM.
The robust evidence of the impact of MBS on T2DM
amelioration has led major scientific organisations, such as the American Diabetes Association and the International Diabetes Federation, to recommend bariatric surgery as part of the treatment algorithm for obese patients with T2DM. (9) In Singapore and other Asian countries, the use of MBS to combat the rising trend of obesity and T2DM has grown in popularity. From 2004 to 2009, the absolute number of bariatric surgery procedures conducted in Asia increased by 5.5 times, from 381 to 2,091 surgical procedures. (10) Within the Asian population, bariatric surgery has also resulted in significant and sustained weight loss, with a T2DM remission rate of up to 80% in morbidly obese Asian patients. (11) However, multi-ethnicity in Singapore poses an interesting challenge in the management of T2DM and obesity. In 2010, the National Health Survey (NHS) revealed that with the rise in obesity prevalence from 6.9% in 2004 to 10.8% in 2010, the prevalence of T2DM had risen significantly from 8.2% to 11.3%, a relative rise of 38% in a timespan of just six years. (12, 13) The prevalence of T2DM was noted to be highest in Indians (17.2%), followed by Malays (16.6%) and Chinese (9.7%). (13) The ethnic group that had the highest proportion of DM patients with poor glycaemic control was the Malays (47.6%), followed by the Indians (37.9%) Patients had to meet the criteria for MBS, which was based on Singapore's Ministry of Health guidelines, (15) and have their medical management optimised before undergoing either laparoscopic sleeve gastrectomy (SG) or laparoscopic GB. The laparoscopic procedures were performed by a single surgeon.
Laparoscopic SG was performed as reported previously. (16) Roux-en-Y GB was also performed laparoscopically, creating a 30-mL gastric pouch using an endoscopic stapler and biliary and alimentary limbs measuring 100 cm each. (17) Patients were selected to undergo either laparoscopic SG or laparoscopic GB based on their baseline profile, and after the surgeon and endocrinologist involved had discussed the risks and benefits of each procedure with the patient. Patients who attended regular follow-up and had at least a year of follow-up data were included in the study.
The primary outcome measure was good glycaemic control at 12 months after surgery. This was defined as HbA1c < 6.5%, with or without medications. The rates of DM remission were studied as a secondary measure.
Using recently published consensus definitions, (18) we defined partial DM remission as HbA1c < 6.5% and FBG < 7.0 mmol/L, and complete remission as HbA1c < 6%
and FBG < 5.6 mmol/L. For patients to be considered to be in remission, they must also not be on any DM with a mean HbA1c of 8.6% (range 7.2%-10.1%). These nine patients were able to achieve a mean HbA1c of 6.3%
without insulin treatment at 12 months postoperatively. difference between the AWLs of the two groups. The GB group started out with a higher HbA1c (8.5%) than the SG group (7.0%). At three months, there was a marked decrease in HbA1c of 2.2% in the GB group vs. 1% in the SG group (Fig. 1) . At 12 months, the reduction in HbA1c from 8.5% to 6.0% was statistically significant in the GB group (p < 0.001), while that in the SG group was not (from Table II . Table III shows the medication use of the patients at baseline and at 12 months. On an average, patients were taking two glucose-lowering agents, two antihypertensives and one lipid-lowering drug (median values) prior to MBS.
At 12 months, there was a significant reduction in the majority of medication classes used for glycaemic, blood pressure and lipid control (Fig. 2) .
DIsCUssION
In our study, patients with T2DM showed dramatic improvements in their weight and glycaemic control after MBS. The significance of this finding carries even more weight when we take into account the marked reduction in the number of DM medications prescribed 12 months after MBS, as compared to before MBS. Weight gain, which occurs with time, is inevitable with various treatments for glycaemic control, especially if treatment is intensified to achieve tight control. This is supported by the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, in which patients with T2DM were randomised to either 
The impact of MBS on amelioration and improvement of T2DM in our series is consistent with observational studies on bariatric procedures, which showed a T2DM remission rate of 55% -95%. (20) In our study, marked reductions in postoperative weight and HbA1c are observed even at three months (Fig. 1) . It is well known that weight corresponds closely with glycaemic control; the Action For Health in Diabetes (Look AHEAD) study has shown that weight loss via diet and exercise improves glycaemic control. (21) However, our study found that unlike medical therapy, the improvements in glycaemic control and weight achieved by MBS are sustained over a one-year period. Two recent randomised controlled trials comparing bariatric surgery with intensive medical therapy in T2DM likewise reported that bariatric surgery was more effective in achieving good glycaemic control than intensive medical therapy alone. (22, 23) As the present study was a prospective observational study in a clinical care setting, and not a randomised controlled trial, there were more patients in the GB group (n = 14) than the SG group (n = 5). Since current evidence suggests that bypass procedures of fer greater DM benefits, (20, 24) patients with poorly controlled T2DM were advised to undergo GB. This explains the higher HbA1c baseline in the GB group (8.5%) as compared to the SG group (7.3%). Our study suggests that although the patients in the GB group had worse glycaemic control at baseline, they still managed to achieve a similar degree of good glycaemic control as the SG group, despite both groups achieving a similar degree of weight loss. The rise in HDL cholesterol and reduction in triglycerides levels were also more significant in the GB group. While this difference could be attributed to the unbalanced sample size of the two groups and the higher HbA1c baseline in the GB group, there is growing evidence that suggests GB may offer greater metabolic benefits than SG.
In a recent study on a Taiwanese population, 60 patients with T2DM were randomised to undergo either GB or SG. (24) At one year, there was a statistically greater number of patients in the GB group who achieved DM remission as compared to the SG group (93% vs. 47%). Greater weight loss and reduction in waist circumference and blood lipid levels were also seen in the GB group. (24) This phenomenon has been well described in other studies, which indicate that gastrointestinal bypass techniques improve glucose homeostasis through mechanisms beyond weight loss and reduced calorie intake. (25) In Singapore, the difference in the prevalence of T2DM in each ethnicity is paralleled by the degree of abdominal fatness (measured by waist-hip ratio), with Indians having the highest prevalence for both. (13) According to the 2010 National Health Survey, (13) Apart from the inherent limitation of our study due to its observational nature, other limitations include a small sample size. The present study may not be adequately powered to detect significant differences in other metabolic parameters, especially between GB and SG, as well as among the various ethnic groups. Despite these limitations, we observed a significant reduction in HbA1c and triglycerides levels, and an increase in HDL levels in the GB group when compared to the SG group. We also believe that the results of our study corroborate the fact that the international recommendation of MBS as an effective treatment modality for obese patients with T2DM is relevant to our local population. Consistent with other studies, our study suggests that MBS is effective in not only achieving significant weight loss, but also improving the glycaemic control of patients with T2DM. This improvement is associated with a reduction in medication use and other cardiovascular risk factors, particularly a significant increment of HDL cholesterol levels, which may reduce cardiovascular disease burden in the future. A randomised controlled trial comparing GB and SG, using a larger sample population powered to look into the effects of both procedures on glycaemic control in each ethnic group, will be useful.
